Monsanto

Monsanto, the US biotech group fined in an English court last week for failing to control genetic modification trials, is under attack on two new fronts. First for obtaining an advance look at confidential European Commission documents during its campaign to win regulatory approval for its controversial bovine growth hormone (BST). Second, because of its legal actions against hundreds of North American farmers for failing to pay for its genetically modified seeds.